Articles by Alessandro Armuzzi

P-061 Impact of Dose Escalation with Anti-TNFs on Healthcare Resource Utilization Among Patients with Crohn's Disease: A Multi-Country Chart Review

Pérez Gisbert, Javier; Patel, Haridarshan; Nguyen, Geoffrey; More

Inflammatory Bowel Diseases. 23:S25, February 2017.

The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar

Fiorino, Gionata; Manetti, Natalia; Armuzzi, Alessandro; More

Inflammatory Bowel Diseases. 23(2):233-243, February 2017.

Fecal HMGB1 Reveals Microscopic Inflammation in Adult and Pediatric Patients with Inflammatory Bowel Disease in Clinical and Endoscopic Remission

Palone, Francesca; Vitali, Roberta; Cucchiara, Salvatore; More

Inflammatory Bowel Diseases. 22(12):2886-2893, December 2016.

Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis

Armuzzi, Alessandro; Pugliese, Daniela; Danese, Silvio; More

Inflammatory Bowel Diseases. 20(8):1368-1374, August 2014.

Role of HMGB1 as a Suitable Biomarker of Subclinical Intestinal Inflammation and Mucosal Healing in Patients with Inflammatory Bowel Disease

Palone, Francesca; Vitali, Roberta; Cucchiara, Salvatore; More

Inflammatory Bowel Diseases. 20(8):1448-1457, August 2014.

Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission

Armuzzi, Alessandro; Pugliese, Daniela; Danese, Silvio; More

Inflammatory Bowel Diseases. 19(5):1065-1072, April 2013.

Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: A real-life multicenter...

Danese, Silvio; Mocciaro, Filippo; Guidi, Luisa; More

Inflammatory Bowel Diseases. 14(8):1168-1170, August 2008.